yes+++

(Basic) ICU Hemodynamic “Secrets” - Part1: I know you know them, but let’s remind ourselves of some basic hemodynamic "secrets":

Iloprost for the Treatment of Severe Septic Shock with Persistent Hypoperfusion: A Double-Blind, Randomized Controlled Trial In patients with septic shock and persistent hypoperfusion, iloprost did not reduce organ failure @matthieulegrand 🔗 https://t.co/VOXAZRJ6D4

The Blue Journal thanks François Dépret, MD, PhD, for his contribution to the July issue Iloprost for the Treatment of Severe Septic Shock with Persistent Hypoperfusion: A Double-Blind, Randomized Controlled Trial @matthieulegrand https://t.co/70w97sAYUx

Iloprost for the Treatment of Severe Septic Shock with Persistent Hypoperfusion: A Double-Blind, Randomized Controlled Trial CCR Journal Watch - tracking the critical care literature daily https://t.co/Sp06oA6IDG

Join AJRCCM, JAMA, and NEJM at “Discussions on the Edge” on Monday, May 19 Session B2. Pulmonary 9:15 a.m. Room 25 Hall E (North Building, Exhibition Level), Moscone Center Session B92. Critical Care 2:15 p.m. Room 25 Hall E (North Building, Exhibition Level), Moscone Center

Dear friends and colleagues, It is with overwhelming sadness that we share news of the death of our colleague, mentor and friend, Rinaldo Bellomo. During recent days, both he and his family have received dedicated, expert and compassionate care from some of the finest in our ICU

Postoperative Outcomes Among Sodium-Glucose Cotransporter 2 Inhibitor Users. What are the impart of SGLT2 inhibitors on postoperative outcomes? What are the risk of euglycemic keto-acidosis in patients treated with SGLT2 inhibitors and undergoing surgery?

ISICARE - In response to numerous requests last week, we’ve decided to extend this special offer for an additional week, until the end of the early bird rate, March 31! Register now & take advantage of this unique opportunity! https://t.co/tXH9pGpQuX #ISICARE @FilippoAnnoni4

#𝐈𝐒𝐈𝐂𝐄𝐌𝟐𝟓 – 𝐓𝐡𝐚𝐧𝐤 𝐘𝐨𝐮! An incredible few days of learning, collaboration & innovation! Huge thanks to our attendees, speakers & partners—your dedication is inspiring. The story continues… See you at #ISICEM26 or our next meetings! #ICUcommunity #ISICEMers

Do you remember? This week only, #ISICEM25 attendees can enjoy an exclusive extra discount on the early bird registration for our brand-new #ISICARE congress! 🎥 Watch now as Prof. Filippo Annoni shares more details! 🔗 Register now: https://t.co/tXH9pGpQuX

Some people have asked for full text access to my essay titled, Making Time - A Meta Static Journey. Here is a link:

So well said Mark ! 👏👏👏

Should you stop or continue ACEi/ARBs before surgery? New summary by the STOP-or-NOT trial investigators. No difference in mortality & major complications, but greater incidence of hypotension in patients who continued therapy. #hypotension #surgery #BP https://t.co/S91ERB6Iuj

Here is the best explanation why I LOVE America so much! https://t.co/NR4TyZq8wY

#CritCare #OpenAccess The renin–angiotensin–aldosterone-system in sepsis and its clinical modulation with exogenous angiotensin II Read the full article: https://t.co/LQrr0rnYED @jlvincen @ISICEM #FOAMed #FOAMcc

Honored to contribute to this consensus paper on alterations in the renin-angiotensin system and the use of exogenous angiotensin II in septic shock! @pwierusz @matthieulegrand @KhannaAshishCCM @KatarzynaKotfis @MarliesOst @giovannilandoni @ferrer_ricard @MarcLeone8

Viewpoint by Richard Platt, @HaydenBosworth, and Gregory Simon discusses the challenges of implementing findings from pragmatic clinical trials in health care systems. https://t.co/qSK4elA0wK

Check out the new BJA Special Issue on #sustainability in anaesthesia. Guested edited by Prof Jodi Sherman. https://t.co/SMxWKltqg7

1/ @yourICM's latest articles: ICU toolbox Topical Collection 🔹How to manage sodium-glucose cotransporter-2 inhibitors in the critically ill patient? 👉 https://t.co/klCw8OGUK6